Patient characteristics and univariate analysis results
| Clinical demographic characteristics | All patients, n (%) | Non-responders (PRU >208; n=21), % | Responders (PRU ≤208; n=94), % | P value |
| Age, years (mean±SD) | 58.3±10.1 | 59.6±8.2 | 58.0±10.5 | 0.43 |
| Men | 85 (73.9) | 57.1 | 77.7 | 0.061 |
| BMI (kg/m2) | 29.6±5.8 | 31.8±6.1 | 29.1±5.6 | 0.03 |
| eGFR (mL/min/1.73 m2) | 1.02±0.51 | 0.88±0.24 | 0.071 | |
| Haemoglobin (g/dL) | 12.28±2.17 | 14.33±1.95 | <0.001 | |
| HTN | 69 (60.0) | 57.1 | 60.6 | 0.81 |
| Diabetes | 48 (41.7) | 71.4 | 35.1 | 0.003 |
| Smoking | 24 (20.9) | 19 | 21.3 | 0.92 |
| Previous IHD | 47 (40.9) | 33.3 | 42.6 | 0.59 |
| Previous PCI | 28 (24.3) | 0 | 29.8 | 0.003 |
| Medications used | ||||
| Aspirin | 101 (87.8) | 85.7 | 88.3 | 0.72 |
| Clopidogrel | 88 (76.5) | 52.4 | 81.9 | 0.008 |
| Beta-blocker | 84 (73.0) | 76.2 | 72.3 | 0.8 |
| ACEI/ARB | 58 (50.4) | 52.4 | 50 | 1 |
| Statin | 101 (87.8) | 71.4 | 91.5 | 0.021 |
| Atorvastatin | 66 (57.4) | 42.9 | 60.6 | 0.011 |
| Rosuvastatin | 31 (27.0) | 23.8 | 27.7 | 0.05 |
| Fluvastatin | 2 (1.7) | 4.8 | 1.1 | 0.84 |
| Simvastatin | 2 (1.7) | 0 | 2.1 | 0.24 |
| PPI | 12 (10.4) | 9.5 | 10.6 | 0.62 |
| Insulin | 10 (8.7) | 9.5 | 8.5 | 0.58 |
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; eGFR, estimated glomerular filtration rate; HTN, hypertension; IHD, ischaemic heart disease; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor; PRU, P2Y12 reaction unit.